MedTrace Logo

Assessing the Safety of Buprenorphine in People With Sickle Cell Disease

NCT03492099 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2022-04-25

Study results available
· View outcomes & findings →

Summary

This study will assess the safety of changing pain medications (opioids) adult sickle cell patients take to another type of medication therapy (buprenorphine). Patients will be asked questions about their quality of life. Other tools for assessment will also be administered.

Conditions

Interventions

DRUG

buprenorphine

Patients in this study will receive dosages to be determined by a physician that are specific to each patient.

Sponsors & Collaborators

Principal Investigators

  • Sophie Lanzkron, MD, MHS · Johns Hopkins University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-09-23
Completion
2022-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03492099 on ClinicalTrials.gov